Long-term Efficacy of Siponimod Treatment for up to 5 Years in Patients with Secondary Progressive Multiple Sclerosis: Analysis of the EXPAND Extension Study

被引：0

作者：

Kappos, L. ^{[1
,2
,3
,4
,5
]}

Giovannoni, G. ^{[6
]}

Gold, R. ^{[7
]}

Fox, R. J. ^{[8
]}

Vermersch, P. ^{[9
]}

Benedict, R. H. B. ^{[10
]}

Bar-or, A. ^{[11
,12
]}

Rouyrres, N. ^{[13
]}

Piani-Meier, D. ^{[13
]}

Ritter, S. ^{[14
]}

Kilaru, A. ^{[13
]}

Dahlke, F. ^{[13
]}

Karlsson, G. ^{[13
]}

Cree, B. A. C. ^{[15
]}

机构：

[1] Univ Hosp, Dept Med, Neurol Clin & Policlin, Basel, Switzerland

[2] Univ Hosp, Dept Clin Res, Neurol Clin & Policlin, Basel, Switzerland

[3] Univ Hosp, Dept Biomed, Neurol Clin & Policlin, Basel, Switzerland

[4] Univ Hosp, Dept Biomed Engn, Neurol Clin & Policlin, Basel, Switzerland

[5] Univ Basel, Basel, Switzerland

[6] Queen Mary Univ London, Barts & London Sch Med & Dent, Blizard Inst, London, England

[7] Ruhr Univ Bochum, Dept Neurol, St Josef Hosp, Bochum, Germany

[8] Cleveland Clin, Neurol Inst, Mellen Ctr Treatment & Res Multiple Sclerosis, Cleveland, OH 44106 USA

[9] Univ Lille, CHU Lille, FHU Imminent, INSERM,U995, Lille, France

[10] SUNY Buffalo, Dept Neurol, Buffalo, NY USA

[11] Univ Penn, Perelman Sch Med, Ctr Neuroinllammat & Expt Therapeut, Philadelphia, PA 19104 USA

[12] Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA 19104 USA

[13] Novartis Pharma AG, Basel, Switzerland

[14] Novartis Pharmaceut, E Hanover, NJ USA

[15] Univ Calif San Francisco, Dept Neurol, UCSE Weill Inst Neurosci, San Francisco, CA USA

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

EPR2128

引用

页码：337 / 337

页数：1

共 50 条

[21] Effect of Siponimod on Grey Matter Atrophy in Patients with Secondary Progressive Multiple Sclerosis: Subgroup Analyses from the EXPAND Study
Vennersch, P.
Fox, R. J.
Arnold, D. L.
Giovannoni, G.
Cree, B. A. C.
Bar-Or, A.
Golds, R.
Benedict, R. H. B.
Piaui-Meier, D.
Arnould, S.
Ritter, S.
Dahlke, F.
Karlsson, G.
Kappos, L.
[J]. EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 478 - 478
[22] Effect of siponimod on cortical grey matter and thalamic volume in patients with secondary progressive multiple sclerosis - results of the EXPAND study
Arnold, D. L.
Fox, R.
Bar-Or, A.
Cree, B. A. C.
Giovannoni, G.
Gold, R.
Vermersch, P.
Meier, D. Piani
Arnould, S.
Ritter, S.
Dahlke, F.
Tomic, D.
Kappos, L.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 151 - 152
[23] Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
Kappos, Ludwig
Bar-Or, Amit
Cree, Bruce
Fox, Robert
Giovannoni, Gavin
Gold, Ralf
Vermersch, Patrick
Lam, Elaine
Pohlmann, Harold
Zhang-Auberson, Lixin
Dandekar, Atul
Wallstroem, Erik
[J]. NEUROLOGY, 2013, 80
[24] Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis: Design of the Phase 3 EXPAND Trial
Kappos, L.
Bar-Or, A.
Cree, B.
Fox, R.
Giovannoni, G.
Gold, R.
Vermersch, P.
Lam, E.
Pohlmann, H.
Zhang-Auberson, L.
Dandekar, A.
Wallstrom, E.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 927 - 928
[25] Baseline Subgroup Characteristics of EXPAND: A Phase 3 Study of Siponimod (BAF312) for the Treatment of Secondary Progressive Multiple Sclerosis
Kappos, Ludwig
Bar-Or, Amit
Cree, Bruce
Fox, Robert
Giovannoni, Gavin
Gold, Ralf
Vermersch, Patrick
Bhasin, Priya
Arnould, Sophie
Sidorenko, Tatiana
Wallstroem, Erik
[J]. NEUROLOGY, 2016, 86
[26] Magnetization Transfer Imaging in Secondary Progressive Multiple Sclerosis Patients Treated with Siponimod: Results from the Phase 3 EXPAND Study
Arnold, Douglas L.
Cree, Bruce A. C.
Bar-Or, Amit
Giovannoni, Gavin
Gold, Ralf
Vermersch, Patrick
Meier, Daniela Piani
Arnould, Sophie
Ritter, Shannon
Karlsson, Goeril
Kappos, Ludwig
Fox, Robert
[J]. NEUROLOGY, 2020, 94 (15)
[27] Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study
Cohen, Jeffrey A.
Khatri, Bhupendra
Barkhof, Frederik
Comi, Giancarlo
Hartung, Hans-Peter
Montalban, Xavier
Pelletier, Jean
Stites, Tracy
Ritter, Shannon
von Rosenstiel, Philipp
Tomic, Davorka
Kappos, Ludwig
[J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 (05): : 468 - 475
[28] Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis
Regner-Nelke, Liesa
Pawlitzki, Marc
Willison, Alice
Rolfes, Leoni
Oezalp, Sinem-Hilal
Nelke, Christopher
Koelsche, Tristan
Korsen, Melanie
Grothe, Matthias
Groppa, Sergiu
Luessi, Felix
Engel, Sinah
Nelles, Gereon
Bonmann, Eckhard
Roick, Holger
Friedrich, Anke
Knorn, Philipp
Landefeld, Harald
Biro, Zoltan
Ernst, Michael
Bayas, Antonios
Menacher, Martina
Akgun, Katja
Kleinschnitz, Christoph
Ruck, Tobias
Ziemssen, Tjalf
Pul, Refik
Meuth, Sven G.
[J]. NEUROLOGICAL RESEARCH AND PRACTICE, 2022, 4 (01):
[29] Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
Ralf Gold
Daniela Piani-Meier
Ludwig Kappos
Amit Bar-Or
Patrick Vermersch
Gavin Giovannoni
Robert J. Fox
Douglas L. Arnold
Ralph H. B. Benedict
Iris-Katharina Penner
Nicolas Rouyrre
Ajay Kilaru
Göril Karlsson
Shannon Ritter
Frank Dahlke
Thomas Hach
Bruce A. C. Cree
[J]. Journal of Neurology, 2022, 269 : 5093 - 5104
[30] Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study
Gold, Ralf
Piani-Meier, Daniela
Kappos, Ludwig
Bar-Or, Amit
Vermersch, Patrick
Giovannoni, Gavin
Fox, Robert J.
Arnold, Douglas L.
Benedict, Ralph H. B.
Penner, Iris-Katharina
Rouyrre, Nicolas
Kilaru, Ajay
Karlsson, Goril
Ritter, Shannon
Dahlke, Frank
Hach, Thomas
Cree, Bruce A. C.
[J]. JOURNAL OF NEUROLOGY, 2022, 269 (09) : 5093 - 5104

← 1 2 3 4 5 →